Skip to Content

Press Releases

Press Releases

Apr 09 2017
Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman
JERUSALEM, April 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced the appointment of Jeffrey A.
Apr 07 2017
Intec Pharma Reports 2016 Fourth Quarter and Full Year Financial Results
JERUSALEM, April 7, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq and TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today reported financial results for the three and 12 months ended December 31,
Mar 29 2017
Intec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill Carbidopa/Levodopa in Parkinson's Disease Patients
Expects to Complete Enrollment in the Fourth Quarter of 2017 JERUSALEM, March 29, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today provided an
Mar 22 2017
Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies
JERUSALEM, March 22, 2017 /PRNewswire/ -- Expects Phase I Results in the Third Quarter of 2017 Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a
Mar 17 2017
Intec Pharma to Participate in the Oppenheimer 27th Annual Healthcare Conference
JERUSALEM, March 17, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Company will participate at the Oppenheimer 27th Annual Healthcare
Mar 10 2017
Intec Pharma to Participate in the 29th Annual Roth Conference
ntec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Company management will participate at the 29 th  Annual Roth Conference taking place from March 13-15, 2017 at the Ritz
Mar 10 2017
Intec Pharma Announces $10 Million Private Placement
JERUSALEM, March 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ; TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has entered into agreements with several investors for the
Nov 28 2016
Intec Pharma Enters into Agreement with the Michael J. Fox Foundation Around Its Phase III Trial Recruitment
JERUSALEM, November 28, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces it has entered into an agreement with the Michael J.
Nov 09 2016
Intec Pharma to Sponsor Investigator Meeting for Pivotal Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
JERUSALEM, November 9, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announces that the Company will be hosting an investigator meeting
Nov 07 2016
Intec Pharma Announces Protocol Amendment to Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Sample size reduced from 460 to 328 patients without altering the trial's objectives, endpoints or statistical powering JERUSALEM, November 7, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its
Displaying 41 - 50 of 74